Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0YZYDS |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Her2-PT-A114C-hGl |
|||||
| Synonyms |
Her2-PT-A114C-hGl
Click to Show/Hide
|
|||||
| Antigen Name | Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Her2-PT-A114C-hGl- LP2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
3.58 ng/ml
|
Negative HER2 expression (HER2-) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
4.66 ng/ml
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
7.07 ng/ml
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-361-DYT2 cells | CVCL_0620 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
13.86 ng/ml
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | Invasive breast carcinoma | BT-474 cells | CVCL_0179 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
189 ng/ml
|
Negative HER2 expression (HER2-) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
Her2-PT-A114C-hGl-LP48 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
9.71 ng/ml
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
29.08 ng/ml
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | Invasive breast carcinoma | BT-474 cells | CVCL_0179 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
42.58 ng/ml
|
Negative HER2 expression (HER2-) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
64.65 ng/ml
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-361-DYT2 cells | CVCL_0620 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
578 ng/ml
|
Negative HER2 expression (HER2-) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||